CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $520,738.00 in Stock

Posted by Francis Steltz on Aug 24th, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) Director Andrew Schwab sold 114,700 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $4.54, for a total value of $520,738.00. Following the transaction, the director owned 2,465,298 shares in the company, valued at $11,192,452.92. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

CAMP4 Therapeutics Stock Performance

Shares of NASDAQ:CAMP opened at $4.48 on Monday. The firm has a market cap of $281.12 million, a price-to-earnings ratio of -1.93 and a beta of 0.22. The stock’s 50-day moving average price is $4.12 and its two-hundred day moving average price is $4.34. CAMP4 Therapeutics Corporation has a 12-month low of $1.41 and a 12-month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million for the quarter. As a group, research analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Piper Sandler restated an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Finally, Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CAMP4 Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $9.56.

View Our Latest Stock Report on CAMP4 Therapeutics

Institutional Investors Weigh In On CAMP4 Therapeutics

Several large investors have recently made changes to their positions in CAMP. Bridgeway Capital Management LLC acquired a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at $36,000. China Universal Asset Management Co. Ltd. purchased a new stake in CAMP4 Therapeutics during the 4th quarter worth $61,000. Jefferies Financial Group Inc. acquired a new stake in CAMP4 Therapeutics in the 4th quarter valued at $70,000. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics in the second quarter valued at about $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in CAMP4 Therapeutics in the fourth quarter valued at about $115,000.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.